Efficient whole-cell bioconversion of indole-3-lactate by metabolic engineering of high-glucose-adaptive Lactiplantibacillus plantarum.
Abstract
Bio-production of the high-value health-promoting metabiotic indole-3-lactate (3-ILA) by lactic acid bacteria (LAB) and bifidobacteria remains constrained to micromolar levels. This limitation is largely due to pyruvate outcompeting indole-3-pyruvate (3-IPYA) for LDH and NADH, leading to lactate accumulation and suppressed 3-ILA synthesis. In this study, previously developed high-glucose-adaptive Lactiplantibacillus plantarum strains LP-D-4G and LP-D-10E were evaluated as chassis for enhanced 3-ILA production. Compared with the parental strain, the adaptive strains exhibited increased l-tryptophan (l-Trp) utilization and 3-ILA production during resting-cell bioconversion, together with altered pyruvate-derived product distributions and intracellular NAD(H) profiles. Systematic genome mining and heterologous expression in Escherichia coli identified five active lactate dehydrogenases (LDH2/3/5/6/7) and one aromatic-amino-acid aminotransferase (ArAT2). Co-expression of LDH7 and ArAT2 in strain LP-D-4G achieved 6.06 mM 3-ILA, 0.95 mol/mol l-Trp conversion, and a 3-ILA/(3-ILA + lactate) ratio of 0.31 mol/mol in whole-cell bioconversion. Furthermore, optimization of l-Trp and glucose feeding strategies improved 3-ILA production. In a scaled-up 150-mL fed-batch system, strain LP-D-4G overexpressing LDH7 and ArAT2 produced 20.09 mM 3-ILA at 96 h, representing the highest titer reported to date for LAB-based 3-ILA production. At peak, 3-ILA yield, productivity, and the 3-ILA/(3-ILA + lactate) ratio reached 0.84 mol/mol l-Trp, 69.45 mg/L/h, and 0.25 mol/mol, respectively. This study establishes a food-grade platform for bioactive 3-ILA production and demonstrates an effective strategy to reduce lactate and enhance 3-ILA by combining a high-glucose-adaptive chassis with pathway reinforcement.